fda tirzepatide shortage update Says Compounded Must Exit the Market In blow to compounders, FDA

Tirzepatide is a cutting-edge injectable medication that combines the action of two hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)to promote weight loss and improve metabolic health

Flexible Payment Options: Affordable self-pay plans and insurance support available for all patients

You can read the full article at Tirzepatide demonstrated significant weight loss superiority over placebo at 72 weeks in Eli Lilly and Companys SURMOUNT-1 clinical trial, achieving up to 22.5% body weight reduction among participants without diabetes and with obesity or overweight plus comorbidities

Currently available anti-obesity medications have shown a modest weight reduction of approximately 5% compared to a placebo when used over the long term